Completed A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database NCT05236257 Conditions Infantile Fibrosarcoma, Locally Advanced or Metastatic Infantile Fibrosarcoma Harboring an NTRK Gene Fusion Locations Multiple Locations — Multiple Locations, France View Trial Details
Active, Not Recruiting A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors NCT03899792 Conditions Adenocarcinoma, Adenocarcinoma, Papillary, Breast Diseases, +52 more Locations Childrens Hospital of Los Angeles — Los Angeles, California, United States The Children's Hospital for Cancer and Blood Disorders — Aurora, Colorado, United States Nemours Children's Health — Orlando, Florida, United States Dana-Farber Cancer Institute — Boston, Massachusetts, United States View all 26 locations View more locations Show fewer locations Loading locations... View Trial Details
Active, Not Recruiting Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia NCT03834961 Conditions Central Nervous System Neoplasm, Central Nervous System Neoplasms, Infantile Fibrosarcoma, +7 more Locations Children's Hospital of Alabama — Birmingham, Alabama, United States Arkansas Children's Hospital — Little Rock, Arkansas, United States Kaiser Permanente Downey Medical Center — Downey, California, United States Children's Hospital Los Angeles — Los Angeles, California, United States View all 80 locations View more locations Show fewer locations Loading locations... View Trial Details
